NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

Feuerstein made this comment one month before Celldex’s Rintega spectacularly failed, with a hazard ratio its primary investigator later likened to the treatment effect against GBM of “water.”

“I have been bullish on Celldex and Rintega because the company has presented data from previous studies (like REACT) which, to me, make a convincing and supportive case for the drug benefitting GBM patients. Celldex has much more credibility than Northwest Biotherapeutics, which excels at promotional claims about its GBM immunotherapy but can't support any of them with convincing clinical data.” — Adam Feuerstein

January 28, 2016.

Rintega failed 40 days later. Congratulations AF — eyeroll.